Navigation Links
Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
Date:1/17/2012

MARLBOROUGH, Mass., Jan. 17, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that a new study in the Journal of Cardiovascular Electrophysiology demonstrates the high acute and chronic success rates achievable with a single AF ablation procedure using HeartLight EAS. The study was conducted by Boris Schmidt, MD, and colleagues at Cardioangiologisches Centrum Bethanien, Frankfurt, Germany, and was published online in January 2012.

The HeartLight EAS is a catheter ablation system that incorporates, for the first time, an endoscope for direct visualization of a beating heart, in real-time and without radiation. It also includes a compliant, dynamically adjustable balloon catheter designed for improved contact with the pulmonary vein (PV) ostium (opening) irrespective of the individual patient anatomy, and utilizes laser energy for more efficient, durable and precise ablation treatment.

"Pulmonary vein isolation is a critical indicator of success in catheter ablation procedures for AF; however, this has traditionally been a very challenging and complex endeavor requiring an experienced operator, multiple ablation devices to account for varied patient anatomy, and even multiple transseptal punctures for access," said Dr. Schmidt. "In this study we set out to examine the feasibility of performing a streamlined, visually-guided ablation procedure and record best practices to achieve endpoints of acute and chronic success.  Our findings demonstrate that this unique approach to ablation may prove highly effective in treating AF patients."

In the study, "Visually Guided Sequential Pulmonary Vein Isolation: Insights into Techniques and Predictors of Acute Success," physicians performed ablation with a single HeartLight EAS and single transseptal puncture on 35 patients with drug-refractory paroxysmal or persistent AF. PV isolation was achieved in 70% (96/137) of veins with an initial ablation. After assessment with a circular mapping catheter, continued ablation with the same HeartLight EAS device resulted in an overall 98% single procedure PV isolation rate. 

Procedures were performed in a mean time of 154+ 38 min, with the ablation stage lasting an average of 89+ 16 min and mean fluoroscopy time of 16 + 6 min. Notably, between the first and last 12 cases a reduction in procedure time was observed (175 + 48 min vs. 138 + 26 min). The primary efficacy endpoint of the study was acute PVI, with a secondary endpoint of freedom from AF between 90 and 365 days post-ablation and off antiarrythmic drugs. During a median follow-up of 266 days, 77% (27/35) of patients remained free of any tachyarrhythmia recurrence and off drugs.

"With the increasing use of catheter ablation as a treatment option for AF patients, the short learning curve and simplified approach enabled by the HeartLight EAS makes this a very promising system, especially as the technique continues to be adopted outside specialized ablation centers," continued  Dr. Schmidt. "In the paper we documented our approach to performing ablation on our center's first series of patients to undergo treatment with the HeartLight EAS, and we believe that as the procedure continues to be standardized, additional centers will experience these impressive, reproducible results."

"In this study, physicians have demonstrated a high rate of clinical success achievable within a reasonably short procedure time, even among operators still in the midst of the learning curve," said Stephen Sagon, President and CEO of CardioFocus. "This reinforces the advantages of HeartLight EAS' novel, adaptable and user-friendly design, and we look forward to continued positive experiences from this and other medical centers as they begin to standardize and master this ablation approach."

For more information on HeartLight EAS, please visit www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.

B Schmidt et al: Visually Guided Sequential Pulmonary Vein Isolation: Insights into Techniques and Predictors of Acute Success. Journal of Cardiovascular Electrophysiology. 2012 Jan 9; DOI: 10.1111/j.1540-8167.2011.02247.x http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.2011.02247.x/abstract

 Company Contact:

Media Contact:Anjie Roldan

 Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com

 


'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
2. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
3. Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
4. Dermatologist Amy Taub, MD, is Published in the Journal of Clinical and Aesthetic Dermatology
5. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
6. American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville
7. Data Published in Circulation Journal Show OrbusNeichs Genous™ Stent Is Safe and Effective in Elderly Patients
8. Ion Torrent CEO Jonathan Rothberg, Life Technologies Recognized by Wall Street Journal Technology Innovation Awards for the Ion Personal Genome Machine
9. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
10. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
11. Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):